Browsing Tag
JELMYTO
3 posts
UroGen takes $7m IntraGel stake as local oncology pipeline expands beyond bladder cancer
UroGen Pharma is investing up to $7 million in IntraGel Therapeutics while securing options on TumoCure and as many as three additional oncology programs built around sustained local drug delivery.
Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology.
Will UroGen Pharma’s reimbursement tailwind in 2026 turn ZUSDURI into a category-defining cancer therapy?
UroGen Pharma sets $1B peak sales goal for ZUSDURI as permanent J-code from 2026 is expected to drive widespread adoption in outpatient urology settings.